Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081523 · ClinicalTrials.gov registry record
Natural History of Sickle Cell Disease
A clinical trial of Pain Crisis, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- 3,500
- Enrollment target
- 3
- Study locations
NCT00081523: Recruiting study of Pain Crisis, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00081523 is a study of Pain Crisis that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 3,500 participants. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00081523, a study of Pain Crisis, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- 3,500 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated. Subjects will receive their general medical care outside the NIH and will be seen at our clinic or at CNHS with varying frequency. Subjects may be seen for multiple visits. Subjects may be asked to return for additional testing as needed. Clinical care for patients with sickle cell disease will be provided as appropriate through the Sickle Cell Clinic and the inpatient clinical center....
Primary Outcome
Better characterization of the natural history of sickle cell disease
Conditions Studied
Study Locations (3)
Maryland
- Suburban Hospital - Bethesda
- National Institutes of Health Clinical Center - Bethesda
District of Columbia
- Childrens National Health Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,500 participants |
| Start Date | 2004-04-29 |
What NCT00081523 shows while recruiting
NCT00081523 is an observational study that tracks outcomes without assigning an intervention. Its 3,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Pain Crisis appearing as the primary indexed condition, and to 0 interventions.
NCT00081523 reports a single indexed study location in Maryland, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00081523 about?
NCT00081523 is a clinical study titled "Natural History of Sickle Cell Disease". This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated. Subjects will receive their general medical care outside the NIH and will be seen at our cli...
What is the current status of trial NCT00081523?
This trial is currently recruiting. The enrollment target is 3,500 participants. The study started on 2004-04-29.
What conditions does trial NCT00081523 study?
This clinical trial studies the following conditions: Pain Crisis.
Who is sponsoring clinical trial NCT00081523?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00081523 being conducted?
This trial has 3 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI